530 related articles for article (PubMed ID: 21592595)
21. Maternal disruption of Ube3a leads to increased expression of Ube3a-ATS in trans.
Landers M; Calciano MA; Colosi D; Glatt-Deeley H; Wagstaff J; Lalande M
Nucleic Acids Res; 2005; 33(13):3976-84. PubMed ID: 16027444
[TBL] [Abstract][Full Text] [Related]
22. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes.
Chamberlain SJ; Chen PF; Ng KY; Bourgois-Rocha F; Lemtiri-Chlieh F; Levine ES; Lalande M
Proc Natl Acad Sci U S A; 2010 Oct; 107(41):17668-73. PubMed ID: 20876107
[TBL] [Abstract][Full Text] [Related]
23. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
24. Potential therapeutic approaches for Angelman syndrome.
Bi X; Sun J; Ji AX; Baudry M
Expert Opin Ther Targets; 2016; 20(5):601-13. PubMed ID: 26558806
[TBL] [Abstract][Full Text] [Related]
25. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
Elgersma Y; Sonzogni M
Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
[TBL] [Abstract][Full Text] [Related]
26. Conserved UBE3A subcellular distribution between human and mice is facilitated by non-homologous isoforms.
Zampeta FI; Sonzogni M; Niggl E; Lendemeijer B; Smeenk H; de Vrij FMS; Kushner SA; Distel B; Elgersma Y
Hum Mol Genet; 2020 Nov; 29(18):3032-3043. PubMed ID: 32879944
[TBL] [Abstract][Full Text] [Related]
27. Molecular epigenetics of Angelman syndrome.
Lalande M; Calciano MA
Cell Mol Life Sci; 2007 Apr; 64(7-8):947-60. PubMed ID: 17347796
[TBL] [Abstract][Full Text] [Related]
28. The E6-Ap ubiquitin-protein ligase (UBE3A) gene is localized within a narrowed Angelman syndrome critical region.
Sutcliffe JS; Jiang YH; Galijaard RJ; Matsuura T; Fang P; Kubota T; Christian SL; Bressler J; Cattanach B; Ledbetter DH; Beaudet AL
Genome Res; 1997 Apr; 7(4):368-77. PubMed ID: 9110176
[TBL] [Abstract][Full Text] [Related]
29. Genomic imprinting does not reduce the dosage of UBE3A in neurons.
Hillman PR; Christian SGB; Doan R; Cohen ND; Konganti K; Douglas K; Wang X; Samollow PB; Dindot SV
Epigenetics Chromatin; 2017; 10():27. PubMed ID: 28515788
[TBL] [Abstract][Full Text] [Related]
30. [From pathogenesis to treatment of genetic intellectual disabilities: a lesson from Angelman syndrome research].
Saitoh S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Jun; 33(3):127-30. PubMed ID: 25069246
[TBL] [Abstract][Full Text] [Related]
31. CRISPR/Cas9 directed to the Ube3a antisense transcript improves Angelman syndrome phenotype in mice.
Schmid RS; Deng X; Panikker P; Msackyi M; Breton C; Wilson JM
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33411694
[TBL] [Abstract][Full Text] [Related]
32. The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology.
Dindot SV; Antalffy BA; Bhattacharjee MB; Beaudet AL
Hum Mol Genet; 2008 Jan; 17(1):111-8. PubMed ID: 17940072
[TBL] [Abstract][Full Text] [Related]
33. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations.
Bossuyt SNV; Punt AM; de Graaf IJ; van den Burg J; Williams MG; Heussler H; Elgersma Y; Distel B
Hum Mol Genet; 2021 Apr; 30(6):430-442. PubMed ID: 33607653
[TBL] [Abstract][Full Text] [Related]
34. Imprinting in Angelman and Prader-Willi syndromes.
Jiang Y; Tsai TF; Bressler J; Beaudet AL
Curr Opin Genet Dev; 1998 Jun; 8(3):334-42. PubMed ID: 9691003
[TBL] [Abstract][Full Text] [Related]
35. Angelman syndrome-derived neurons display late onset of paternal UBE3A silencing.
Stanurova J; Neureiter A; Hiber M; de Oliveira Kessler H; Stolp K; Goetzke R; Klein D; Bankfalvi A; Klump H; Steenpass L
Sci Rep; 2016 Aug; 6():30792. PubMed ID: 27484051
[TBL] [Abstract][Full Text] [Related]
36. 1031-1034delTAAC (Leu125Stop): a novel familial UBE3A mutation causing Angelman syndrome in two siblings showing distinct phenotypes.
De Molfetta GA; Ferreira CA; Vidal DO; Giuliani Lde R; Maldonado MJ; Silva WA
BMC Med Genet; 2012 Dec; 13():124. PubMed ID: 23256887
[TBL] [Abstract][Full Text] [Related]
37. Altered ultrasonic vocalization and impaired learning and memory in Angelman syndrome mouse model with a large maternal deletion from Ube3a to Gabrb3.
Jiang YH; Pan Y; Zhu L; Landa L; Yoo J; Spencer C; Lorenzo I; Brilliant M; Noebels J; Beaudet AL
PLoS One; 2010 Aug; 5(8):e12278. PubMed ID: 20808828
[TBL] [Abstract][Full Text] [Related]
38. Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.
Ramirez J; Lectez B; Osinalde N; Sivá M; Elu N; Aloria K; Procházková M; Perez C; Martínez-Hernández J; Barrio R; Šašková KG; Arizmendi JM; Mayor U
Hum Mol Genet; 2018 Jun; 27(11):1955-1971. PubMed ID: 29788202
[TBL] [Abstract][Full Text] [Related]
39. Angelman syndrome: a review of the clinical and genetic aspects.
Clayton-Smith J; Laan L
J Med Genet; 2003 Feb; 40(2):87-95. PubMed ID: 12566516
[TBL] [Abstract][Full Text] [Related]
40. HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.
Wang T; Wang J; Wang J; Mao L; Tang B; Vanderklish PW; Liao X; Xiong ZQ; Liao L
Neurobiol Dis; 2019 Dec; 132():104585. PubMed ID: 31445164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
